Actinium Pharmaceuticals, Inc.
New York, US
Actinium is developing targeted radiotherapy treatments using Actinium-225 and related isotopes for oncology indications including prostate cancer, non-small cell lung cancer, breast cancer, and acute myeloid leukemia. The company's lead candidates include ATNM-400 for solid tumors and Actimab-A for blood malignancies.
Founders & leadership
DC
Dragan CicicChief Operating Officer and Chief Medical Officer
ST
Sergio TraversaInterim Chief Financial Officer
KJ
Kaushik J. DavePresident and Chief Executive Officer
SS
Sandesh SethinChairman of the Board
Board
DN
David NicholsonBoard director
RI
Richard I. SteinhartBoard director
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 1 round · 2013
▶$6.6MraisedJan 2014 · 63 investors · PharmaceuticalsRule 506(b)
▶$6.6MraisedJan 2014 · 63 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dragan CicicExecutive Officer
- David NicholsonDirector
- Sergio TraversaExecutive Officer, Director
- Kaushik J. DaveExecutive Officer, Director
- Sandesh SethDirector
- Richard I. SteinhartDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- Minimum investment
- $5K
- Sales commissions
- $663.7K
- Placement agents
- Recipient Laidlaw & Company (UK) Ltd.
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2023 | $865.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $378.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Actinium Pharmaceuticals, Inc. do?
- Actinium is developing targeted radiotherapy treatments using Actinium-225 and related isotopes for oncology indications including prostate cancer, non-small cell lung cancer, breast cancer, and acute myeloid leukemia. The company's lead candidates include ATNM-400 for solid tumors and Actimab-A for blood malignancies.
- How much funding has Actinium Pharmaceuticals, Inc. raised?
- Actinium Pharmaceuticals, Inc. has disclosed $6.6M raised across 1 round.
- Where is Actinium Pharmaceuticals, Inc. headquartered?
- Actinium Pharmaceuticals, Inc. is headquartered in New York, US.